| ID | 10376 |
| Vaccine Name | Covishield |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Non-replicating viral vector |
| Vaccine Status | Phase 4 |
| Manufacturer | AstraZeneca plc, University of Oxford, Serum Institute of India |
| Year of Manufacturing | 2020 |
| Manufacturing Country | UK |
| Age | 18 years and above |
| Dosage | 2 doses 4 to 12 weeks apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Spike protein of SARS-CoV-2 virus |
| Description | ChAdOx1 technology |
| Approving Organisation | NA |
| Collaborating Organisation | University of Oxford |
| Other Countries | Japan, Korea, India |
| Trade Name | AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines |
| Additional Links | NA
|